

# CEN TOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109 Asset Class: **Stock**

## Company

2024/05/17 22:00:00



Price

**0.37** USD

Difference ▼ -2.63% (-0.01)



## Contact Details

CEN TOGENE NV Tel: +49-381-80113400  
 -- Fax: +381-80113401  
 Am Strande 7 Web: <http://www.centogene.com>  
 18055 Rostock E-mail: -

## Company Profile

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	63,855,000		58,539,000		118,740,000	
<b>Common stock capital</b>		3,529,000		3,079,000		3,247,000
<b>Fixed assets</b>	35,197,000		44,597,000		64,950,000	
<b>Equity capital of a company</b>		7,909,000		31,276,000		80,481,000
<b>Cash and cash equivalents</b>	38,368,000		20,262,000		58,921,000	
<b>Accrued liabilities</b>		277,000		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		26,323,000		44,914,000		69,886,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		57,683,000		17,816,000		22,372,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		616,000		0		0
<b>Total assets</b>	99,053,000	99,053,000	103,137,000	103,137,000	183,691,000	183,691,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	517	808	657
<b>Equity ratio</b>	7.98%	30.54%	43.88%
<b>Debt-equity ratio</b>	1,152.35%	227.46%	127.91%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	-0.28%	0.05%	-1.33%

# CENTOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109 Asset Class: **Stock**

## Income statement

	2022	2021	2020
<b>Turnover</b>	49,892,000	224,485,000	146,351,000
<b>Net income</b>	-40,675,000	-55,494,000	-24,438,000
<b>EBIT</b>	-33,809,544	-49,964,834	-21,007,102
<b>Operating income before taxes</b>	-40,563,000	-55,406,000	-24,050,000
<b>Cash Flow</b>	-32,997,000	-26,007,000	9,456,000
<b>Net interest income</b>	-3,749,000	-1,002,000	-1,176,000
<b>Research and development expenses</b>	15,303,000	18,198,000	15,582,000
<b>Income taxes</b>	112,000	-28,000	320,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	88,630	255,158	204,580

## Board of Directors

Peer Schatz	Chairman of Supervisory Board
Eric Sou�tre	Member of Supervisory Board
Flemming �rnskov	Member of Supervisory Board
Hubert Birner	Member of Supervisory Board
Jonathan Sheldon	Member of Supervisory Board
Guido Prehn	Member of Supervisory Board
Mary Sheahan	Member of Supervisory Board

## Members of Management Board

Kim Stratton	Chairman of Managing Board
Bettina Goerner	Member of Executive Committee
Ian Rentsch	Member of Executive Committee
Miguel Coego Rios	Member of Executive Committee
Patrice P. Den�fle	Member of Executive Committee
Peter Bauer	Member of Executive Committee